“Abstract
Ivermectin was shown to inhibit severe acute respiratory syndrome coronavirus 2 replication in vitro, which has led to off-label use, but clinical efficacy has not been described previously…
Methods
Sequentially consecutive hospitalized patients at four Broward Health-associated hospitals in South Florida with laboratory-confirmed infection with SARS-CoV-2 during their admission were reviewed in this study...
Patients were categorized into two treatment groups based on whether they received ivermectin at any time during the hospitalization...
Results
Three hundred seven patients were admitted for COVID-19 during the period studied... The remaining cohort of 280 patients comprised 173 treated with ivermectin and 107 in the usual care group...
Unadjusted outcomes for the unmatched cohort and outcomes in the propensity-matched cohort are shown in Table 2. For the unmatched cohort, overall mortality was significantly lower in the ivermectin group than in the usual care group (15.0% vs 25.2% for ivermectin and usual care, respectively; P = .03). Mortality also was lower for ivermectin-treated patients in the subgroup of patients with severe pulmonary involvement (38.8% vs. 80.7% for ivermectin and usual care, respectively; P = .001).”
Copyright © 2020 The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).